New Study Finds Continuous, Noninvasive Hemoglobin Monitoring Using Masimo SpHb® May Reduce Intraoperative Red Blood Cell Tr...
September 09 2016 - 8:03AM
Business Wire
Masimo (NASDAQ: MASI) announced today that in a new study
recently presented at the World Congress of Anesthesiologists (WCA)
in Hong Kong, researchers concluded that continuous and noninvasive
hemoglobin monitoring using Masimo SpHb® may reduce excessive
intraoperative red blood cell (RBC) transfusion.1
In a retrospective review of 371 patients who underwent
intraoperative RBC transfusions between 2012 and 2014 at Fukushima
Medical University in Japan, Dr. Imaizumi and colleagues compared
94 patients who had noninvasive hemoglobin measurements to 277
patients who did not (the control group). The total transfusion
volumes and transfusion volume per 1 g of blood loss were
determined for each group.
Comparing the groups, researchers noted that “a significantly
lower mean RBC transfusion volume per 1 g of blood loss was
observed in the SpHb group compared with the [control] group (SpHb
group, 0.9 ± 1.0 ml/g blood loss vs [control] group, 2.4 ± 5.9 ml/g
blood loss, p < 0.01).” They also observed that there was “no
significant difference…in the average RBC transfusion volume (SpHb
group, 815 ± 819 ml vs. [control] group, 785 ± 773 ml, p=0.75), or
the preoperative hemoglobin concentration (SpHb group, 10.4 ± 1.9
g/dL vs. [control] group, 10.2 ± 2.4 g/dL, p=0.27) between the
groups.” According to results from this abstract, the authors
concluded that “SpHb measurements are associated with reducing
excessive intraoperative RBC transfusion.”
“This is the third study, published by different researchers on
three continents (US2, Egypt3, and now Japan1), that has shown that
in addition to other clinical tools, SpHb may be used to help
clinicians make informed transfusion decisions during different
types of surgery*,” stated Dr. Steven Barker, Ph.D., M.D., Chief
Science Officer, Masimo.
SpHb monitoring may provide additional insight to the
directional trend of hemoglobin between invasive blood samplings –
when the SpHb trend is stable and the clinician may otherwise think
hemoglobin is decreasing; when the SpHb trend is rising and the
clinician may otherwise think hemoglobin is not rising fast enough;
or when the SpHb trend is decreasing and the clinician may
otherwise think hemoglobin is stable. SpHb with laboratory
diagnostic test may thus help clinicians make more timely and
informed decisions, and has been shown to help clinicians provide
more timely blood transfusions* and reduce blood transfusions in
cases such as neurosurgery and orthopedic surgery.2,3
Last week Masimo announced that in response to the Zika virus
and its potential impact on the availability of blood products,
Masimo has created a special program to dramatically reduce the
cost of and increase access to Masimo’s SpHb solutions, as SpHb has
been shown to help clinicians reduce blood transfusions in both low
and high blood loss surgery. This special program will be available
wherever the blood supply is affected by the Zika virus.
@MasimoInnovates | #Masimo
*Clinical decisions regarding red blood cell transfusions should
be based on the clinician’s judgment considering, among other
factors: patient condition, continuous SpHb monitoring, and
laboratory diagnostic tests using blood samples.
References
- Imaizumi et al. Continuous and
noninvasive hemoglobin monitoring may reduce excessive
intraoperative RBC transfusion. Proceedings from the 16th World
Congress of Anaesthesiologists, Hong Kong. Abstract #PR607.
- Ehrenfeld JM et al. J Blood Disorders
Transf. 2014. 5:9. 2.
- Awada WN et al. J Clin Monit Comput.
2015 Feb 4.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care by taking noninvasive
monitoring to new sites and applications. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world.
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more
recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index
(ORI™), in addition to SpO2, pulse rate, and perfusion index (PI).
In 2014, Masimo introduced Root®, an intuitive patient monitoring
and connectivity platform with the Masimo Open Connect™ (MOC-9™)
interface. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7™ wearable patient
monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at
www.masimo.com. All published clinical studies on Masimo products
can be found at
http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of SpHb® and the availability
of Masimo’s special program for SpHb solutions. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SpHb, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions with comparable accuracy and unique
advantages, including: immediate and continuous results that enable
earlier treatment without causing invasive trauma in all patients
and in every clinical situation; as well as other factors discussed
in the "Risk Factors" section of our most recent reports filed with
the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations
will prove correct. All forward-looking statements included in this
press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of today's date. We do not undertake any obligation to
update, amend or clarify these statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as
a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160909005161/en/
MasimoEvan Lamb, 949-396-3376elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024